• Adaptive Dengue Antiviral Platform Trial

  NCT06551844

  RecruitingInterventionalPhase 2Updated Apr 30, 2026
• Ketotifen as a Treatment for Vascular Leakage During Dengue Fever

  NCT02673840

  Unknown statusInterventionalPhase 4Updated Feb 4, 2016
• Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults

  NCT02392325

  CompletedInterventionalPhase 1Updated Feb 8, 2018
• Study to Examine the Effects of Oral Fenretinide

  NCT06528457

  CompletedInterventionalPhase 2Updated Oct 24, 2025
• Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore

  NCT02569827

  WithdrawnInterventionalPhase 1Phase 2Updated Mar 23, 2020
• Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection

  NCT07706686

  RecruitingInterventionalPhase 1Updated Aug 13, 2026

ClinicalTrials.gov ID

NCT07543458

Lead Sponsor

Oxford University Clinical Research Unit, VietnamOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

8,800Estimated

Last Update Posted

Apr 21, 2026Actual

Start Date

Oct 1, 2026Estimated

Primary Completion Date

Jul 31, 2030Estimated

Completion Date

Jul 31, 2031Estimated

Official Title

A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)

Brief Summary

The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.

Detailed Description

This multi-site, factorial randomised, platform clinical trial will evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. The primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.

The trial will employ partial factorial randomization. Participants who provide informed consent will be entered into one or more randomisations, depending on eligibility for each intervention, clinician discretion, and availability of the treatment at the study site. For each intervention, eligible participants will be randomised in a 1:1 ratio to receive either the active intervention or the corresponding control (either matched placebo or usual care, depending on the intervention). Participants who are ineligible for a specific treatment comparison may still enter other treatment comparisons within the trial.

Outcomes are described in more detail in the outcome section below. Participants will be followed up until death/day 30 after randomisation (whichever is sooner) to monitor for primary, secondary and safety outcomes. Participants who have been discharged from hospital alive before day 30 will have a final assessment conducted by telephone at least 30 days after randomisation.

Patients will be additionally consented for collection of a blood sample, taken and stored as a dried blood spot, for analyses in genetic studies and other research.

• Dengue
• Severe Dengue
• Mosquito-Borne Diseases
• Vector Borne Diseases
• Arbovirus Infections
• Flavivirus Infections
• RNA Virus Infections
• Hemorrhagic Fever

• Placebo
• Dexamethasone
• N-Acetylcysteine
• Standard of care
• Baricitinib

Ages Eligible for Study

Child (0-17)Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age ≥5 years

• Decision to hospitalise

• Clinical diagnosis of dengue

• Participants must also have at least one of the following:

  1. Severe abdominal pain or tenderness
  2. Vomiting more than 3 times in the past 24 hours
  3. Pleural effusion or ascites on clinical or radiological examination
  4. Absolute haematocrit >50%
  5. 15% increase in haematocrit compared with a baseline sample (defined as the first sample taken during the current illness)
  6. Absolute platelet count <50 × 10⁹/L
  7. Absolute platelet count <100 × 10⁹/L AND a drop >50 × 10⁹/L in the past 32 hours
  8. ALT or AST >400 IU/L
  9. Pulse pressure <20mmHg or hypotension for age AND at least one of: peripheral capillary refill time >2 seconds; urine output 0.5ml/kg/hr; cold/clammy peripheries; agitation or altered mental state
  10. Bleeding leading to hypotension for age or requiring blood transfusion or medical intervention (e.g. surgery, endoscopy, or vasoactive drugs)
  11. Symptomatic bleeding into a critical site (intracranial, intraspinal, intraocular with visual impairment, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome)
  12. Requirement for organ support, including vasopressors or inotropes, assisted ventilation, dialysis or haemofiltration, or coma (unresponsive to pain without sedation) or requirement for intravenous antiseizure medications

Exclusion Criteria:

• Patients on ≥ day 10 of illness or who are clinically improving in the opinion of the managing doctor (the 'recovery phase') will be excluded from recruitment. Other exclusion criteria are specific to individual treatment comparisons, and do not preclude randomisation to other arms of the study.
• A participant may not enter a specific treatment comparison if that treatment is considered to be indicated or contraindicated by the responsible clinician.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Factorial Assignment

Masking

Quadruple

Lead Sponsor

Oxford University Clinical Research Unit, VietnamOTHER

Collaborators

University of OxfordOTHER

Hospital for Tropical Diseases, Ho Chi Minh City, VietnamOTHER

Number 2 Children's Hospital, Ho Chi Minh CityOTHER

Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, NepalUNKNOWN

National Academy of Medical Sciences/Bir Hospital, Kathmandu, NepalUNKNOWN

Siriraj HospitalOTHER

Prince of Songkla University in Southern Thailand, ThailandUNKNOWN

Dhaka Medical CollegeOTHER

Chittagong Medical College and HospitalOTHER

Centro de Atención y Diagnóstico de Enfermedades Infecciosas, Bucaramanga, ColombiaUNKNOWN

Hospital Universitario Erasmo Meoz, Cucuta, ColombiaUNKNOWN

Fundación Valle del Lili, Cali, ColombiaUNKNOWN

Hospital Regional de Loreto, Iquitos, PeruUNKNOWN

Instituto de Infectologia Emílio Ribas, São Paulo, BrazilUNKNOWN

Universitas Sumatera Utara, Medan, IndonesiaUNKNOWN

Airlangga University (UNAIR), IndonesiaUNKNOWN

University Malaya Medical Centre, MalaysiaUNKNOWN

Hospital Queen Elizabeth II, MalaysiaUNKNOWN

San Lazaro Hospital (SLH-NU), Manila, PhilippinesUNKNOWN

chisti@icddrb.org,

lubabashahrin@icddrb.org

claudia.mello@emilioribas.sp.gov.br

centrodeinvestigaciones@fvl.org.co

inke.nadia@usu.ac.id

gsrajahram@gmail.com

gipeit@gmail.com

sayoanaria@gmail.com

nasikarn@gmail.com